Halo Neuroscience has received $1.5 million in funding. Andreessen Horowitz and SoftTech VC led the round with participation from Kima Ventures, Fabrice Grinda and Josh Hannah. Based in San Francisco, Halo is a maker of wearable technology that helps brain activity.
Halo Neuroscience closes $1.5mm round led by Marc Andreessen for Andreessen Horowitz and Jeff Clavier for SoftTech VC
Halo Neuroscience is developing wearable technology that boosts brain function. Simple to use, safe, instant effect with enduring benefit, the vision of Halo’s technology is the ability to augment the highest human faculties. The brain is already a powerful computing system, yet Halo’s neuromodulation technology has the potential to improve cognitive performance even in healthy brains.
Halo’s technology employs a range of noninvasive, low energy, battery operated stimulation modalities that work on the nervous system to boost cognition. Halo builds on the field ofneuromodulation, where recent science has employed electromagnetic waveforms, infrared light, ultrasound, physical and other stimulation techniques.
Halo was founded by doctors and scientists who are veterans of the pioneering neurostimulation company NeuroPace and consumer tech companies Virgin Mobile, Peek and Fon. Since 2013, Halo has been engineering its commercial product and conducting trials to demonstrate effectiveness.
The scientific advisors are among the top researchers in the world, including:
● clinical scientists from University of California, San Francisco, Burke Institute Cornell and Medical University of South Carolina,
● Silicon Valley innovators behind Google Glass and Android,
● founders of the large new venturebacked health insurer Oscar, and
● Intel board member and former Federal Communications Commission chairman, Reed
The new $1.5 million financing is the company’s first, with firms Andreessen Horowitz, SoftTech VC, and Kima Ventures from Paris participating alongside angels Fabrice Grinda and Josh Hannah.
The company is not disclosing its immediate product plans, citing the important range of intellectual property and safety priorities when working on technologies under federal Food and Drug Administration authority.
Dr. Daniel Chao, the company Chief Executive said “The extraordinary potential of this technology to improve and transform the power of the human brain has yet to be fully realized. Our plan is to bring this futuristic vision to life.”
The company is based in San Francisco.
More information http://www.haloneuro.com.